A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
NCT ID: NCT06648655
Last Updated: 2025-07-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE2
Total Enrollment
110 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-11-14
Study Completion Date
2025-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Medication Development in Alcoholism: Apremilast Versus Placebo
NCT03175549
Alcohol Use Disorder
COMPLETED
PHASE2
Dose-response Study of Apremilast in Women and Men With Alcohol Use Disorder
NCT07029529
Alcohol Use Disorder
NOT_YET_RECRUITING
PHASE2
Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718)
NCT00764660
Alcoholism
TERMINATED
PHASE2
Soberlink Within In-Home Addiction Treatment Program
NCT03902171
Alcohol Use Disorder
UNKNOWN
An Efficacy and Safety Study of Topiramate in the Treatment of Alcohol Dependence
NCT00210925
Alcoholism
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this study is to assess the safety, tolerability and effect on alcohol use (number of heavy drinking days) of TMP-301 compared to placebo in patients with alcohol use disorder. This is a placebo-controlled, parallel-group, multicenter clinical study in moderate to severe alcohol use disorder with ≥8 heavy drinking days over the prior 4 weeks at screening. Study participants and investigators will be blinded to study intervention. The study duration will be up to 19 weeks, with a treatment duration of up to 14 weeks. The visit frequency will be weekly.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alcohol Use Disorder (AUD)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TMP-301
Daily (QD) x 14 weeks.
Group Type
EXPERIMENTAL
TMP-301
Intervention Type
DRUG
Daily (QD) x 14 weeks.
Placebo
Daily (QD) x 14 weeks.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Daily (QD) x 14 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TMP-301
Daily (QD) x 14 weeks.
Intervention Type
DRUG
Placebo
Daily (QD) x 14 weeks.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Provision of signed and dated Informed Consent Form (ICF) with a stated willingness to comply with all study procedures and availability for the duration of the study. A breathalyzer test must be \<0.05% at the time of ICF signing. Participants who have a blood alcohol content between 0.02 and 0.04% inclusive at Screening will be assessed for competency to consent using the UBACC scale. Participants must have a passing score of ≥ 15 during the Screening period to consent and be eligible for randomization.
2. Adult female or male, 18 to 65 years of age inclusive, at the time of screening.
3. Alcohol use disorder, moderate or severe by DSM-5 diagnostic criteria (i.e., ≥4 out of 11 symptoms present using the SCID-5-CT diagnostic interview) at screening for the previous 12 months.
4. At least 8 heavy drinking days over the previous 4 weeks (by Timeline Follow Back) at screening.
* Heavy Drinking Days (HDD): ≥4 drinks/day for females, ≥5 drinks/ day for males.
* A standard drink is defined as 12 ounces (350 ml) of 5% beer, 5 ounces (150 ml) of 12% wine, or 1.5 ounces (44 ml) of 80-proof (40%) distilled spirits.
5. Seeking treatment for AUD, with a desire to reduce or cease alcohol use at screening.
6. Breathalyzer \<0.05% at baseline..
7. BMI of ≥18.0 to ≤40.0 kg/m2 at screening.
8. No clinically significant findings (in the investigator's opinion) on physical exam, ECG, vital signs, or clinical laboratory tests at screening. The following criteria must be met:
* Systolic Blood Pressure (SBP) 90-140 mmHg, and Diastolic Blood Pressure (DBP) 50-90 mmHg, inclusive (average of three readings) at screening and baseline.
* Alanine transaminase (ALT) and Aspartate transferase (AST) \< 3x upper limit of normal, and total bilirubin \< upper limit of normal (isolated elevated total bilirubin is allowed if Gilbert's syndrome is the suspected etiology)..
* Estimated Glomerular Filtration Rate (eGFR) ≥ 60 mL/min/1.73 m2
* Negative urine drug screen for cocaine or stimulants at screening and baseline
9. Able to communicate well and understand written instructions.
10. Agree to practice highly effective birth control starting at screening and continuing for 30 days (females) or 90 days (males) after study treatment ends.
1. For females any of the following (no donation of eggs/ova is allowed):
* Abstinence from heterosexual intercourse.
* Postmenopausal: absence of menses ≥ 12 months (without an alternative medical condition) and Follicle-Stimulating Hormone (FSH) ≥ 40 mIU/mL at screening.
* Surgically sterile: bilateral oophorectomy, salpingectomy, tubal ligation, or hysterectomy ≥180 days prior to screening.
* Contraceptive implant or intrauterine device.
2. For males any of the following (no donation of sperm is allowed):
* Abstinence from heterosexual intercourse.
* Male condom with spermicide or male condom with vaginal spermicide (gel, foam, or suppository).
* Surgically sterile: post vasectomy or bilateral orchiectomy
2. Adult female or male, 18 to 65 years of age inclusive, at the time of screening.
3. Alcohol use disorder, moderate or severe by DSM-5 diagnostic criteria (i.e., ≥4 out of 11 symptoms present using the SCID-5-CT diagnostic interview) at screening for the previous 12 months.
4. At least 8 heavy drinking days over the previous 4 weeks (by Timeline Follow Back) at screening.
* Heavy Drinking Days (HDD): ≥4 drinks/day for females, ≥5 drinks/ day for males.
* A standard drink is defined as 12 ounces (350 ml) of 5% beer, 5 ounces (150 ml) of 12% wine, or 1.5 ounces (44 ml) of 80-proof (40%) distilled spirits.
5. Seeking treatment for AUD, with a desire to reduce or cease alcohol use at screening.
6. Breathalyzer \<0.05% at baseline..
7. BMI of ≥18.0 to ≤40.0 kg/m2 at screening.
8. No clinically significant findings (in the investigator's opinion) on physical exam, ECG, vital signs, or clinical laboratory tests at screening. The following criteria must be met:
* Systolic Blood Pressure (SBP) 90-140 mmHg, and Diastolic Blood Pressure (DBP) 50-90 mmHg, inclusive (average of three readings) at screening and baseline.
* Alanine transaminase (ALT) and Aspartate transferase (AST) \< 3x upper limit of normal, and total bilirubin \< upper limit of normal (isolated elevated total bilirubin is allowed if Gilbert's syndrome is the suspected etiology)..
* Estimated Glomerular Filtration Rate (eGFR) ≥ 60 mL/min/1.73 m2
* Negative urine drug screen for cocaine or stimulants at screening and baseline
9. Able to communicate well and understand written instructions.
10. Agree to practice highly effective birth control starting at screening and continuing for 30 days (females) or 90 days (males) after study treatment ends.
1. For females any of the following (no donation of eggs/ova is allowed):
* Abstinence from heterosexual intercourse.
* Postmenopausal: absence of menses ≥ 12 months (without an alternative medical condition) and Follicle-Stimulating Hormone (FSH) ≥ 40 mIU/mL at screening.
* Surgically sterile: bilateral oophorectomy, salpingectomy, tubal ligation, or hysterectomy ≥180 days prior to screening.
* Contraceptive implant or intrauterine device.
2. For males any of the following (no donation of sperm is allowed):
* Abstinence from heterosexual intercourse.
* Male condom with spermicide or male condom with vaginal spermicide (gel, foam, or suppository).
* Surgically sterile: post vasectomy or bilateral orchiectomy
Exclusion Criteria
1. History of hypersensitivity to TMP-301 or other mGluR5 antagonists.
2. Evidence of suicidal risk as assessed by the Columbia-Suicide Severity Rating Scale at screening or baseline as follows:
* Suicidal Ideation Section: "Yes" on item 4 or 5 if within 6 months of screening or between screening and baseline.
* Suicidal Behavior Section: "Yes" on any item (except non-suicidal self-injurious behavior) if within 2 years of screening or between screening and baseline.
3. Significant risk of acute alcohol withdrawal syndrome (either of the following):
* Any history of Delirium Tremens or seizures from alcohol withdrawal.
* Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) score \>7 at screening or baseline.
4. Any history of seizures, except febrile seizures as a child.
5. Other (non-alcohol) substance use disorders (by DSM-5) as follows:
* Any cocaine or stimulant use disorder
* Moderate or severe use disorder of all other substances (mild allowed).
6. Use of the following within the last 90 days or ≥ 5 times the half-life prior to randomization:
* Pharmacotherapy for any substance use disorder (e.g.: disulfiram, acamprosate, modafinil, topiramate, or baclofen).
* Use of prescribed methylphenidate or other stimulant.
* Use of any Glucagon-like peptide 1 (GLP-1) agonist for any indication.
7. Past or current history of any mental, behavioral, or neurodevelopmental disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or significant risk of developing a psychosis (assessed by PRIME screen) or a personal history of psychotic symptoms (hallucinations or delusions) with or without a formal psychiatric diagnosis.
* Individuals with AUD or mild other substance use disorder (except for cocaine or stimulants) may participate.
* Individuals who meet criteria for a current major depressive episode are excluded.
8. Requires treatment with any psychoactive medications, including any anti-seizure medications (except medications used for short-term treatment of insomnia).
\- Antidepressant medications are allowed if the patients have been on an adequate and stable dose for at least 3 months prior to study treatment dosing with the exception of CYP1A2 substrates or CYP3A4 inhibitors as detailed in Exclusion 19.
9. Having had initiation of, or change in intensity of, psychotherapy or other non-drug therapies within 6 weeks prior to enrollment or unwillingness to maintain current psychotherapeutic and non-drug therapy levels from screening through the or at any time during the acute treatment phase of the study.
10. Use of other investigational drugs or devices at the time of screening, or within 5 half-lives of randomization, or within 30 days, whichever is longer or has been part of any clinical study within 30 days of randomization.
11. Pregnant or nursing (lactating) females.
12. Recent history or active clinically significant manifestations of metabolic, hepatic, renal (including porphyria), hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, urogenital, neurological, ophthalmic, or ears, nose, and throat (ENT) disorders, or any other acute or chronic condition or medication use that, in the Investigator's opinion, would limit the subject's ability to complete or participate in this clinical study.
13. Concomitant use of agents known to prolong the QT interval unless these can be permanently discontinued for the duration of study.
14. History or current diagnosis of ECG abnormalities at screening indicating significant risk of safety for subjects participating in the study such as:
* Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree Atrioventricular (AV) block without a pacemaker.
* History of familial long QT syndrome or known family history of Torsades de Pointes.
* QTcF \> 450 msec (males); QTcF \> 460 msec (females).
* Note: sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes are not exclusionary.
15. Patients with history of chronic hypertension, unless well controlled by taking antihypertensive treatment at a stable dose for ≥3 months
16. History or presence of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there was evidence of local recurrence or metastases.
17. Detectable hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV) antibody at screening.
\- Participants in remission for HCV or HIV, as demonstrated by a sustained virological response (undetectable viral load) may be enrolled in the study.
18. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.
19. Need/plan to take or substrates of cytochrome P450 (CYP)1A2 or inhibitors of CYP3A4. (Note: CYP1A2 inhibitors are permitted, as they are not expected to increase TMP-301 exposures above what was shown to be safe and generally well-tolerated in study TMP-301- HNV-101.).
* CYP1A2 Substrates: (Exposure could increase when taken with TMP-301):
* alosetron, duloxetine, melatonin, ramelteon, tasimelteon, tizanidine, pimozide, agomelatine, tacrine, clozapine, pirfenidone, theophylline, tacrine, ropivacaine
* CYP3A4 Inhibitors: Could increase TMP-301 exposure at steady- state
* grapefruit juice, Seville orange-containing food (e.g. bitter orange marmalade) or drink (e.g. bitter orange liqueurs including Curaçao and Grand Marnier)
* ketoconazole, diltiazem, verapamil, clarithromycin, itraconazole, erythromycin, fluconazole, ceritinib, cobicistat, idelalisib, indinavir. ritonavir, nefazodone, lopinavir, aprepitant, ciprofloxacin, conivaptan, crizotinib, dronedarone, imatinib
20. Patient cannot:
* Anticipate any significant problems with transportation arrangements or available time to travel to the study site and have any plans to move within the next months to a location which would make continued participation in the study' impractical.
* Be involved in any unresolved legal problems that could jeopardize continuation or completion of the study.
* Have any pending charges for violent crime (not including Driving Under the Influence (DUI) offenses).
* Have any court case with a pending decision that could prohibit participation or compliance in the study.
21. Living situation precludes an ability to adhere to study visits in the opinion of the investigator.
22. Has been previously treated in this study or randomized or treated in any other study employing TMP-301 (i.e., subject may not have received study drug and then reenrolled).
23. Any condition not identified in the protocol that in the opinion of the investigator would confound the evaluation and interpretation of the study data or may put the subject at risk.
2. Evidence of suicidal risk as assessed by the Columbia-Suicide Severity Rating Scale at screening or baseline as follows:
* Suicidal Ideation Section: "Yes" on item 4 or 5 if within 6 months of screening or between screening and baseline.
* Suicidal Behavior Section: "Yes" on any item (except non-suicidal self-injurious behavior) if within 2 years of screening or between screening and baseline.
3. Significant risk of acute alcohol withdrawal syndrome (either of the following):
* Any history of Delirium Tremens or seizures from alcohol withdrawal.
* Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) score \>7 at screening or baseline.
4. Any history of seizures, except febrile seizures as a child.
5. Other (non-alcohol) substance use disorders (by DSM-5) as follows:
* Any cocaine or stimulant use disorder
* Moderate or severe use disorder of all other substances (mild allowed).
6. Use of the following within the last 90 days or ≥ 5 times the half-life prior to randomization:
* Pharmacotherapy for any substance use disorder (e.g.: disulfiram, acamprosate, modafinil, topiramate, or baclofen).
* Use of prescribed methylphenidate or other stimulant.
* Use of any Glucagon-like peptide 1 (GLP-1) agonist for any indication.
7. Past or current history of any mental, behavioral, or neurodevelopmental disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or significant risk of developing a psychosis (assessed by PRIME screen) or a personal history of psychotic symptoms (hallucinations or delusions) with or without a formal psychiatric diagnosis.
* Individuals with AUD or mild other substance use disorder (except for cocaine or stimulants) may participate.
* Individuals who meet criteria for a current major depressive episode are excluded.
8. Requires treatment with any psychoactive medications, including any anti-seizure medications (except medications used for short-term treatment of insomnia).
\- Antidepressant medications are allowed if the patients have been on an adequate and stable dose for at least 3 months prior to study treatment dosing with the exception of CYP1A2 substrates or CYP3A4 inhibitors as detailed in Exclusion 19.
9. Having had initiation of, or change in intensity of, psychotherapy or other non-drug therapies within 6 weeks prior to enrollment or unwillingness to maintain current psychotherapeutic and non-drug therapy levels from screening through the or at any time during the acute treatment phase of the study.
10. Use of other investigational drugs or devices at the time of screening, or within 5 half-lives of randomization, or within 30 days, whichever is longer or has been part of any clinical study within 30 days of randomization.
11. Pregnant or nursing (lactating) females.
12. Recent history or active clinically significant manifestations of metabolic, hepatic, renal (including porphyria), hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, urogenital, neurological, ophthalmic, or ears, nose, and throat (ENT) disorders, or any other acute or chronic condition or medication use that, in the Investigator's opinion, would limit the subject's ability to complete or participate in this clinical study.
13. Concomitant use of agents known to prolong the QT interval unless these can be permanently discontinued for the duration of study.
14. History or current diagnosis of ECG abnormalities at screening indicating significant risk of safety for subjects participating in the study such as:
* Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree Atrioventricular (AV) block without a pacemaker.
* History of familial long QT syndrome or known family history of Torsades de Pointes.
* QTcF \> 450 msec (males); QTcF \> 460 msec (females).
* Note: sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes are not exclusionary.
15. Patients with history of chronic hypertension, unless well controlled by taking antihypertensive treatment at a stable dose for ≥3 months
16. History or presence of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there was evidence of local recurrence or metastases.
17. Detectable hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus (HIV) antibody at screening.
\- Participants in remission for HCV or HIV, as demonstrated by a sustained virological response (undetectable viral load) may be enrolled in the study.
18. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the subject in case of participation in the study.
19. Need/plan to take or substrates of cytochrome P450 (CYP)1A2 or inhibitors of CYP3A4. (Note: CYP1A2 inhibitors are permitted, as they are not expected to increase TMP-301 exposures above what was shown to be safe and generally well-tolerated in study TMP-301- HNV-101.).
* CYP1A2 Substrates: (Exposure could increase when taken with TMP-301):
* alosetron, duloxetine, melatonin, ramelteon, tasimelteon, tizanidine, pimozide, agomelatine, tacrine, clozapine, pirfenidone, theophylline, tacrine, ropivacaine
* CYP3A4 Inhibitors: Could increase TMP-301 exposure at steady- state
* grapefruit juice, Seville orange-containing food (e.g. bitter orange marmalade) or drink (e.g. bitter orange liqueurs including Curaçao and Grand Marnier)
* ketoconazole, diltiazem, verapamil, clarithromycin, itraconazole, erythromycin, fluconazole, ceritinib, cobicistat, idelalisib, indinavir. ritonavir, nefazodone, lopinavir, aprepitant, ciprofloxacin, conivaptan, crizotinib, dronedarone, imatinib
20. Patient cannot:
* Anticipate any significant problems with transportation arrangements or available time to travel to the study site and have any plans to move within the next months to a location which would make continued participation in the study' impractical.
* Be involved in any unresolved legal problems that could jeopardize continuation or completion of the study.
* Have any pending charges for violent crime (not including Driving Under the Influence (DUI) offenses).
* Have any court case with a pending decision that could prohibit participation or compliance in the study.
21. Living situation precludes an ability to adhere to study visits in the opinion of the investigator.
22. Has been previously treated in this study or randomized or treated in any other study employing TMP-301 (i.e., subject may not have received study drug and then reenrolled).
23. Any condition not identified in the protocol that in the opinion of the investigator would confound the evaluation and interpretation of the study data or may put the subject at risk.
Minimum Eligible Age
18 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tempero Bio, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Headlands Research
Scottsdale, Arizona, United States
Site Status
Yale School of Medicine
New Haven, Connecticut, United States
Site Status
Research Centers of America, LLC
Hollywood, Florida, United States
Site Status
CNS Healthcare- Jacksonville South
Jacksonville, Florida, United States
Site Status
Segal Trials - West Broward Outpatient Site
Lauderhill, Florida, United States
Site Status
CNS Healthcare
Orlando, Florida, United States
Site Status
CenExcel iResearch
Decatur, Georgia, United States
Site Status
CenExcel iResearch
Savannah, Georgia, United States
Site Status
DelRicht Research - Murphy Clinic
Mandeville, Louisiana, United States
Site Status
IMA Clinical Research
Albuquerque, New Mexico, United States
Site Status
Neurobehavioral Research, Inc.
Cedarhurst, New York, United States
Site Status
Medical University of South Carolina, Institute of Psychiatry
Charleston, South Carolina, United States
Site Status
Baylor College of Medicine
Houston, Texas, United States
Site Status
University of Virginia: Center for Leading Edge Addiction Research
Charlottesville, Virginia, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMP-301-AUD-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome
NCT03818191
COMPLETED
PHASE4
A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers
NCT02371889
COMPLETED
PHASE2
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
NCT04101227
COMPLETED
PHASE3
Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder
NCT03120468
UNKNOWN
EARLY_PHASE1
Study of Tirzepatide for Recovery and Alcohol Use Management
NCT06727331
RECRUITING
PHASE2
Alcohol Dependency Study: Combining Medication Treatment for Alcoholism
NCT00006205
UNKNOWN
PHASE2
Human Laboratory Study of Apremilast for Alcohol Use Disorder
NCT07325266
NOT_YET_RECRUITING
PHASE2
EMPOWER AUD Pivotal Trial
NCT05948605
COMPLETED
NA
A Targeted, Real-Time, Technology-Supported Intervention for Patients With Alcohol Use Disorder on Disulfiram
NCT03543735
COMPLETED
NA
COMT Inhibition Among Individuals With Comorbid AUD/ADHD
NCT03904498
RECRUITING
PHASE2
Brief New Treatment for Suicide Attempts
NCT03300596
COMPLETED
NA
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
NCT06070649
RECRUITING
PHASE1
Theta Burst Stimulation as a Tool to Decrease Drinking in Treatment-seeking Alcohol Users
NCT04154111
ACTIVE_NOT_RECRUITING
NA
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD
NCT03667846
RECRUITING
PHASE2
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
NCT01408641
TERMINATED
NA
Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence
NCT02120365
COMPLETED
PHASE1/PHASE2
Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.
NCT00366626
COMPLETED
PHASE4
A Study of MK0594 in Patients With Alcohol Dependence (0594-020)
NCT00835718
TERMINATED
PHASE2
Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study
NCT00769158
COMPLETED
PHASE1
Amplification of Positivity for Alcohol Use
NCT06030154
RECRUITING
NA
PT150 Drug for Use in Alcohol Use Disorder
NCT06712602
RECRUITING
PHASE1
Phosphatidylethanol-Based Contingency Management for Housing
NCT04038021
COMPLETED
NA
Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence
NCT03634917
COMPLETED
PHASE3
Effectiveness of Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder
NCT00218725
COMPLETED
PHASE1
Development of a Selective ALDH2 Inhibitor to Treat AUD
NCT04311294
WITHDRAWN
PHASE2